137 related articles for article (PubMed ID: 6576388)
1. Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock.
Fukumoto S; Tanaka K
Prostaglandins Leukot Med; 1983 Jun; 11(2):179-88. PubMed ID: 6576388
[TBL] [Abstract][Full Text] [Related]
2. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
3. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
4. Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency.
Cook JA; Wise WC; Halushka PV
J Clin Invest; 1980 Jan; 65(1):227-30. PubMed ID: 7350199
[TBL] [Abstract][Full Text] [Related]
5. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528
[TBL] [Abstract][Full Text] [Related]
6. [Experimental study on the pathophysiology of endotoxin shock as analysed by alterations in thromboxane B2 and 6-keto-PGF1 alpha levels].
Baba H
Nihon Geka Gakkai Zasshi; 1988 Jan; 89(1):6-20. PubMed ID: 3283521
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous infusion of OKY-1581 (sodium-(E)-3-[4-(3-pyridylmethyl)phenyl] -2-methylacrylate) on circulatory thromboxane A2 and prostacyclin levels in anaesthetized baboon.
Roy AC; Adaikan PG; Karim SM
Prostaglandins Med; 1981 Sep; 7(3):253-9. PubMed ID: 7029585
[No Abstract] [Full Text] [Related]
8. Implications for thromboxane A2 in the pathogenesis of endotoxic shock.
Wise WC; Cook JA; Halushka PV
Adv Shock Res; 1981; 6():83-91. PubMed ID: 6961767
[TBL] [Abstract][Full Text] [Related]
9. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
Hora K; Oguchi H; Furukawa T; Hora K; Tokunaga S
Nephron; 1990; 56(3):297-305. PubMed ID: 2077412
[TBL] [Abstract][Full Text] [Related]
10. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats.
Gomi T; Ikeda T; Ishimitsu T; Uehara Y
Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692
[TBL] [Abstract][Full Text] [Related]
11. Role of thromboxane (Tx) A2 in guinea pig Forssman shock and the effect of OKY-046, Tx A2 synthetase inhibitor.
Nagai H; Yakuo I; Inagaki N; Koda A; Hamano S; Ujiie A; Nakazawa M
Prostaglandins Leukot Med; 1987 Feb; 26(2):133-41. PubMed ID: 3470814
[TBL] [Abstract][Full Text] [Related]
12. The role of thromboxane in primate endotoxin shock.
Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
J Surg Res; 1985 Aug; 39(2):140-9. PubMed ID: 3839548
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane A2 and hemodynamic-biochemical parameters in canine endotoxin shock.
Sakanishi N; Tsunoda Y; Takekawa K; Ikezono E
Bull Tokyo Med Dent Univ; 1983 Jun; 30(2):37-46. PubMed ID: 6580966
[TBL] [Abstract][Full Text] [Related]
14. The role of thromboxane A2 (TxA2) in allergic cutaneous reactions and the effect of (E)-3-[p-(1H-imidazol-1-ylmethyl) phenyl]-2-propenoic acid hydrochloride (OKY-046), a TxA2 synthetase inhibitor.
Nagai H; Yakuo I; Nakatomi I; Inagaki N; Koda A
Prostaglandins Leukot Essent Fatty Acids; 1989 Mar; 35(3):125-30. PubMed ID: 2710796
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of vessel wall prostacyclin by selective thromboxane synthetase inhibitor OKY 1581.
Mehta J; Mehta P; Ostrowski N
Prostaglandins Leukot Med; 1983 Sep; 12(1):49-52. PubMed ID: 6356153
[TBL] [Abstract][Full Text] [Related]
16. Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction.
Tada M; Hoshida S; Kuzuya T; Inoue M; Minamino T; Abe H
Int J Cardiol; 1985 Jul; 8(3):301-12. PubMed ID: 4040500
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane, prostaglandin I2 (epoprostenol), and the hemodynamic changes in equine endotoxin shock.
Bottoms GD; Templeton CB; Fessler JF; Johnson MA; Roesel OF; Ewert KM; Adams SB
Am J Vet Res; 1982 Jun; 43(6):999-1002. PubMed ID: 7049018
[TBL] [Abstract][Full Text] [Related]
18. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531
[No Abstract] [Full Text] [Related]
19. Effects of a pyridine derivative thromboxane synthetase inhibitor and its inactive isomer in endotoxic shock in the rat.
Anderegg K; Anzeveno P; Cook JA; Halushka PV; McCarthy J; Wagner E; Wise WC
Br J Pharmacol; 1983 Apr; 78(4):725-32. PubMed ID: 6687819
[TBL] [Abstract][Full Text] [Related]
20. Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.
Ball HA; Cook JA; Wise WC; Halushka PV
Intensive Care Med; 1986; 12(3):116-26. PubMed ID: 3016060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
